PURPOSE: Chemotherapy treatment may lead to delayed gastric emptying, early satiety, anorexia, nausea and vomiting, described collectively as the cancer-associated dyspepsia syndrome (CADS). METHOD: We examined the effects of ghrelin in rodent models of CADS induced by treatment with cisplatin. RESULTS: In rats, increased gastric contents and reduced feeding were observed 48 h after injection with cisplatin (6 mg/kg, i.p.). Ghrelin (0.5 mg/kg, i.p.) caused a 16-fold increase in food intake over 1 h in cisplatin/ghrelin-treated rats compared to cisplatin/vehicle-treated rats. A single dose of ghrelin also restored the decreased locomotor activity in rats induced by cisplatin to almost the same level of saline-treated rats. In mice, daily food intake was significantly decreased at 24 h (60%) and 48 h (74%) after cisplatin (20 mg/kg, i.p.). Ghrelin (1 mg/kg, i.p.x2) significantly increased food intake measured at the 48 h time-point in both saline/ghrelin-treated and cisplatin/ghrelin-treated mice, with this effect being most marked in the cisplatin-treated group, where a twofold increase in feeding was observed. In cisplatin-treated mice, delayed gastric emptying was indicated by a 7.7-fold increase in the wet weight of gastric contents and ghrelin improved the gastric emptying index (GEI) by 31% (P < 0.01). CONCLUSION: Together, these results suggest that it is possible to model cancer chemotherapy-induced dyspepsia in rodents and that ghrelin can greatly alleviate the behaviours associated with this syndrome. Agonists at the ghrelin receptor may, therefore, become a useful human therapeutic for this disorder.
PURPOSE: Chemotherapy treatment may lead to delayed gastric emptying, early satiety, anorexia, nausea and vomiting, described collectively as the cancer-associated dyspepsia syndrome (CADS). METHOD: We examined the effects of ghrelin in rodent models of CADS induced by treatment with cisplatin. RESULTS: In rats, increased gastric contents and reduced feeding were observed 48 h after injection with cisplatin (6 mg/kg, i.p.). Ghrelin (0.5 mg/kg, i.p.) caused a 16-fold increase in food intake over 1 h in cisplatin/ghrelin-treated rats compared to cisplatin/vehicle-treated rats. A single dose of ghrelin also restored the decreased locomotor activity in rats induced by cisplatin to almost the same level of saline-treated rats. In mice, daily food intake was significantly decreased at 24 h (60%) and 48 h (74%) after cisplatin (20 mg/kg, i.p.). Ghrelin (1 mg/kg, i.p.x2) significantly increased food intake measured at the 48 h time-point in both saline/ghrelin-treated and cisplatin/ghrelin-treated mice, with this effect being most marked in the cisplatin-treated group, where a twofold increase in feeding was observed. In cisplatin-treated mice, delayed gastric emptying was indicated by a 7.7-fold increase in the wet weight of gastric contents and ghrelin improved the gastric emptying index (GEI) by 31% (P < 0.01). CONCLUSION: Together, these results suggest that it is possible to model cancer chemotherapy-induced dyspepsia in rodents and that ghrelin can greatly alleviate the behaviours associated with this syndrome. Agonists at the ghrelin receptor may, therefore, become a useful human therapeutic for this disorder.
Authors: Mohamed A Fahim; Hazem Kataya; Rkia El-Kharrag; Dena Am Amer; Basel al-Ramadi; Sherif M Karam Journal: World J Gastroenterol Date: 2011-09-07 Impact factor: 5.742
Authors: E Z H Sung; R P Arasaradnam; E M Jarvie; S James; S J Goodyear; R A Borman; D Snead; G J Sanger; C U Nwokolo Journal: Mol Biol Rep Date: 2012-06-29 Impact factor: 2.316
Authors: Elena Bresciani; Laura Rizzi; Laura Molteni; Monica Ravelli; Antonella Liantonio; Khoubaib Ben Haj Salah; Jean-Alain Fehrentz; Jean Martinez; Robert J Omeljaniuk; Giuseppe Biagini; Vittorio Locatelli; Antonio Torsello Journal: Endocrine Date: 2016-11-28 Impact factor: 3.633
Authors: Ylva Tiblom Ehrsson; Per M Hellström; Kerstin Brismar; Lena Sharp; Ann Langius-Eklöf; Göran Laurell Journal: Support Care Cancer Date: 2009-10-15 Impact factor: 3.603